The role of innate APOBEC3G and adaptive AID immune responses in HLA-HIV/SIV immunized SHIV infected macaques.

HIV-1 DNA decay dynamics in blood during more than a decade of suppressive antiretroviral therapy. Clin Infect Dis (2014) 1.33

The natural history of HIV infection. Curr Opin HIV AIDS (2013) 0.78

Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011. J Transl Med (2012) 0.75

Translational regulation of APOBEC3G mRNA by Vif requires its 5'UTR and contributes to restoring HIV-1 infectivity. Sci Rep (2016) 0.75

Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature (2002) 21.53

Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell (2000) 20.83

Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol (2000) 20.70

DNA deamination mediates innate immunity to retroviral infection. Cell (2003) 12.10

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61

AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature (2002) 7.12

Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem (1999) 6.67

Mechanism and regulation of class switch recombination. Annu Rev Immunol (2008) 5.98

Retroviral restriction by APOBEC proteins. Nat Rev Immunol (2004) 5.00

The biochemistry of somatic hypermutation. Annu Rev Immunol (2008) 3.78

A formalin-inactivated whole SIV vaccine confers protection in macaques. Science (1989) 3.37

Follicular dendritic cells and human immunodeficiency virus infectivity. Nature (1995) 3.22

Vaccine protection against simian immunodeficiency virus infection. Proc Natl Acad Sci U S A (1989) 3.13

Mechanism and control of class-switch recombination. Trends Immunol (2002) 2.95

Normal T cell homeostasis: the conversion of naive cells into memory-phenotype cells. Nat Immunol (2011) 2.81

Immunity through DNA deamination. Trends Biochem Sci (2003) 2.39

Interaction between antibody-diversification enzyme AID and spliceosome-associated factor CTNNBL1. Mol Cell (2008) 2.39

HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. Nat Immunol (2009) 2.23

Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine. Lancet (1991) 2.10

Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science (1993) 2.08

Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science (2008) 1.97

Stress-activated dendritic cells interact with CD4+ T cells to elicit homeostatic memory. Eur J Immunol (2010) 1.81

B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. J Exp Med (2000) 1.79

AID: how does it aid antibody diversity? Immunity (2004) 1.71

Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J Virol (1995) 1.63

APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J Virol (2010) 1.58

Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS (2009) 1.56

Humoral immunity to HIV-1: neutralization and beyond. J Intern Med (2007) 1.50

Induction of exosome release in primary B cells stimulated via CD40 and the IL-4 receptor. J Immunol (2008) 1.46

Binding of human immunodeficiency virus type-1 to follicular dendritic cells in vitro is complement dependent. J Immunol (1993) 1.45

Dependence of antibody gene diversification on uracil excision. J Exp Med (2007) 1.45

Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J Infect Dis (2010) 1.43

Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc Natl Acad Sci U S A (2010) 1.28

Stimulation of cell surface CCR5 and CD40 molecules by their ligands or by HSP70 up-regulates APOBEC3G expression in CD4(+) T cells and dendritic cells. J Immunol (2007) 1.26

DC-SIGN on B lymphocytes is required for transmission of HIV-1 to T lymphocytes. PLoS Pathog (2006) 1.25

Exosomes packaging APOBEC3G confer human immunodeficiency virus resistance to recipient cells. J Virol (2008) 1.20

Exosome release by primary B cells. Crit Rev Immunol (2009) 1.18

Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. J Virol (2010) 1.15

Allo-immunization elicits CD8+ T cell-derived chemokines, HIV suppressor factors and resistance to HIV infection in women. Nat Med (1999) 1.12

Multifaceted antiviral actions of APOBEC3 cytidine deaminases. Trends Immunol (2006) 1.12

Immune complexes containing human immunodeficiency virus type 1 primary isolates bind to lymphoid tissue B lymphocytes and are infectious for T lymphocytes. J Virol (2000) 1.08

Understand memory, design better vaccines. Nat Immunol (2011) 1.00

The effect of allogeneic in vitro stimulation and in vivo immunization on memory CD4(+) T-cell APOBEC3G expression and HIV-1 infectivity. Eur J Immunol (2009) 0.93

Inhibition of human immunodeficiency virus type 1 infection of human CD4+ T cells by microbial HSP70 and the peptide epitope 407-426. J Virol (2007) 0.92

Mucosal immunization in macaques upregulates the innate APOBEC 3G anti-viral factor in CD4(+) memory T cells. Vaccine (2008) 0.92

A recombinant human HLA-class I antigen linked to dextran elicits innate and adaptive immune responses. J Immunol Methods (2010) 0.85

B-cell agonists up-regulate AID and APOBEC3G deaminases, which induce IgA and IgG class antibodies and anti-viral function. Immunology (2012) 0.81

Protection of macaques against simian immunodeficiency virus infection with inactivated vaccines: comparison of adjuvants, doses and challenge viruses. The European Concerted Action on 'Macaque Models for AIDS Research'. Vaccine (1995) 0.81

Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques. J Virol (2011) 0.80

The kinetics of CD154 (CD40L) expression in peripheral blood mononuclear cells of healthy subjects in liver allograft recipients and X-linked hyper-IgM syndrome. Clin Transplant (2000) 0.80

Heat shock protein 70 inhibits HIV-1 Vif-mediated ubiquitination and degradation of APOBEC3G. J Biol Chem (2011) 0.78

The InterPro Database, 2003 brings increased coverage and new features. Nucleic Acids Res (2003) 24.72

InterPro, progress and status in 2005. Nucleic Acids Res (2005) 17.53

Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA (2009) 12.35

The EMBL Nucleotide Sequence Database. Nucleic Acids Res (2002) 12.05

EMBL Nucleotide Sequence Database in 2006. Nucleic Acids Res (2006) 9.72

The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61

Minimum information about a marker gene sequence (MIMARKS) and minimum information about any (x) sequence (MIxS) specifications. Nat Biotechnol (2011) 7.53

The EMBL Nucleotide Sequence Database. Nucleic Acids Res (2005) 7.18

The EMBL Nucleotide Sequence Database: major new developments. Nucleic Acids Res (2003) 7.17

The EMBL Nucleotide Sequence Database. Nucleic Acids Res (2004) 6.72

The European Nucleotide Archive. Nucleic Acids Res (2010) 6.48

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature (2012) 5.49

Synaptic, transcriptional and chromatin genes disrupted in autism. Nature (2014) 5.30

Petabyte-scale innovations at the European Nucleotide Archive. Nucleic Acids Res (2008) 5.21

EMBL Nucleotide Sequence Database: developments in 2005. Nucleic Acids Res (2006) 5.13

Improvements to services at the European Nucleotide Archive. Nucleic Acids Res (2009) 5.00

Genomewide association studies: history, rationale, and prospects for psychiatric disorders. Am J Psychiatry (2009) 4.74

Exome sequencing and the genetic basis of complex traits. Nat Genet (2012) 4.11

Priorities for nucleotide trace, sequence and annotation data capture at the Ensembl Trace Archive and the EMBL Nucleotide Sequence Database. Nucleic Acids Res (2007) 3.84

Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A (2012) 3.33

Research capacity. Enabling the genomic revolution in Africa. Science (2014) 3.05

Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell (2013) 2.88

Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med (2006) 2.60

Enhanced SIV replication and accelerated progression to AIDS in macaques primed to mount a CD4 T cell response to the SIV envelope protein. Proc Natl Acad Sci U S A (2004) 2.51

Effect of heterosexual intercourse on mucosal alloimmunisation and resistance to HIV-1 infection. Lancet (2004) 2.38

GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort Study. J Infect Dis (2005) 2.33

Early depletion of Mycobacterium tuberculosis-specific T helper 1 cell responses after HIV-1 infection. J Infect Dis (2008) 2.26

Characterization of cereal toxicity for celiac disease patients based on protein homology in grains. Gastroenterology (2003) 2.23

Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol (2008) 2.16

B-cell diversity decreases in old age and is correlated with poor health status. Aging Cell (2008) 2.15

Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J Virol (2003) 2.14

Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS (2008) 2.06

Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol (2007) 2.05

International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One (2009) 2.03

Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting. PLoS One (2011) 1.99

A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J Infect Dis (2011) 1.99

Candidate endophenotypes for genetic studies of suicidal behavior. Biol Psychiatry (2009) 1.98

Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine (2006) 1.97

Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J Infect Dis (2010) 1.95

Major submissions tool developments at the European Nucleotide Archive. Nucleic Acids Res (2011) 1.94

Strategy for the creation of clinical grade hESC line banks that HLA-match a target population. EMBO Mol Med (2012) 1.93

Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses. J Virol (2003) 1.92

Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. J Immunol (2007) 1.89

Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin α4β7. PLoS Pathog (2012) 1.88

High specific infectivity of plasma virus from the pre-ramp-up and ramp-up stages of acute simian immunodeficiency virus infection. J Virol (2009) 1.82

Stress-activated dendritic cells interact with CD4+ T cells to elicit homeostatic memory. Eur J Immunol (2010) 1.81

Effects of CCR5-Delta32 and CCR2-64I alleles on HIV-1 disease progression: the protection varies with duration of infection. AIDS (2003) 1.81

The use of nonhuman primate models in HIV vaccine development. PLoS Med (2008) 1.73

The autism sequencing consortium: large-scale, high-throughput sequencing in autism spectrum disorders. Neuron (2012) 1.71

Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr (2005) 1.68

Meeting report: the fifth Genomic Standards Consortium (GSC) workshop. OMICS (2008) 1.66

Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One (2013) 1.65

Relationship of anti-60 kDa heat shock protein and anti-cholesterol antibodies to cardiovascular events. Circulation (2002) 1.65

The Netherlands Twin Register biobank: a resource for genetic epidemiological studies. Twin Res Hum Genet (2010) 1.65

Interaction between the CCR5 chemokine receptors and microbial HSP70. Eur J Immunol (2006) 1.60

Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett (2004) 1.59

Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol. J Virol (2004) 1.58

Identification of sequential viral escape mutants associated with altered T-cell responses in a human immunodeficiency virus type 1-infected individual. J Virol (2003) 1.57

HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy. AIDS (2008) 1.56

Low-level CD4+ T cell activation is associated with low susceptibility to HIV-1 infection. J Immunol (2005) 1.56

Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques. Proc Natl Acad Sci U S A (2002) 1.55

Stimulation of Th1-polarizing cytokines, C-C chemokines, maturation of dendritic cells, and adjuvant function by the peptide binding fragment of heat shock protein 70. J Immunol (2002) 1.54

The development of CD4 binding site antibodies during HIV-1 infection. J Virol (2012) 1.53

No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial. PLoS Med (2012) 1.52

Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. J Immunol (2002) 1.52

Mycobacterium tuberculosis complex and mycobacterial heat shock proteins in lymph node tissue from patients with pulmonary sarcoidosis. J Clin Microbiol (2006) 1.49

3-Ketosteroid 9alpha-hydroxylase is an essential factor in the pathogenesis of Mycobacterium tuberculosis. Mol Microbiol (2009) 1.48

Association of HLA-C and HCP5 gene regions with the clinical course of HIV-1 infection. AIDS (2009) 1.48

Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge. J Virol (2012) 1.48

Agonist and antagonist recognition by RIG-I, a cytoplasmic innate immunity receptor. J Biol Chem (2008) 1.46

The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog (2008) 1.41

Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life (2002) 1.41

Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology (2006) 1.40

Kinetics of expansion of SIV Gag-specific CD8+ T lymphocytes following challenge of vaccinated macaques. Virology (2005) 1.38

Serum anti-mycobacterial heat shock proteins antibodies in sarcoidosis and tuberculosis. Tuberculosis (Edinb) (2005) 1.37

Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. J Virol (2007) 1.37

Antibodies with high avidity to the gp120 envelope protein in protection from simian immunodeficiency virus SIV(mac251) acquisition in an immunization regimen that mimics the RV-144 Thai trial. J Virol (2012) 1.37

Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc Natl Acad Sci U S A (2010) 1.36

Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease. J Virol (2007) 1.35

Mycobacterium tuberculosis heat shock proteins use diverse Toll-like receptor pathways to activate pro-inflammatory signals. J Biol Chem (2005) 1.34

Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls. PLoS Pathog (2013) 1.33

Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques. J Virol (2004) 1.32

Immune responses induced in cattle by vaccination with a recombinant adenovirus expressing Mycobacterial antigen 85A and Mycobacterium bovis BCG. Infect Immun (2006) 1.32

Caught with their PAMPs down? The extracellular signalling actions of molecular chaperones are not due to microbial contaminants. Cell Stress Chaperones (2010) 1.31

Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology (2004) 1.31

Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression. AIDS (2009) 1.31

The taming of the cell penetrating domain of the HIV Tat: myths and realities. J Control Release (2006) 1.30

Decreasing sensitivity to RANTES (regulated on activation, normally T cell-expressed and -secreted) neutralization of CC chemokine receptor 5-using, non-syncytium-inducing virus variants in the course of human immunodeficiency virus type 1 infection. J Infect Dis (2003) 1.29

Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J Immunol (2004) 1.28

Dendritic cell stimulation by mycobacterial Hsp70 is mediated through CCR5. Science (2006) 1.27

DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime. AIDS Res Hum Retroviruses (2004) 1.27

Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. J Virol (2005) 1.27